Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial
Doi Y, Hamano T, Yamaguchi S, et al.
Diabetes Obes Metab. Pub. online 29 Jun 2023.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Diabetes remission in drug‐naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study
Zeng J, Gan S, Mi N, et al.
Diabetes Obes Metab. Pub. online 29 Jun 2023.
Leggi
A comparison of faster insulin aspart to standard insulin aspart using hybrid automated insulin delivery system in active children and adolescents with type 1 diabetes: a randomized, double-blind crossover trial
Dovc K, Bergford S, Fröhlich-Reiterer E, et al.
Diabetes Technol Ther. Pub. online 5 Jul 2023.
Leggi
Health and economic impact of improved glucose, blood pressure and lipid control among German adults with type 2 diabetes: a modelling study
Fan M, Stephan AJ, Emmert-Fees K, et al.
Diabetologia. Pub. online 30 Jun 2023.
Leggi
The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1‐4 obesity trials
Bjorner JB, Larsen S, Lübker C, Holst-Hansen T
Diabetes Obes Metab. 2023;25(8):2142-2150.
Leggi
Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial
Zhang L, Zhang Y, Shen S, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00132-8.
Leggi
Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial
Svanevik M, Lorentzen J, Borgeraas H, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00127-4.
Leggi
Long‐acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population‐based cohort study
Larose S, Filliter C, Platt RW, et al.
Diabetes Obes Metab. 2023;25(8):2279-2289.
Leggi
Effect of multifactorial intensive treatment in patients with diabetic kidney disease: A meta‐analysis with trial sequential analysis
Shan J, Xu Z
Diabetes Obes Metab. 2023;25(8):2163-2170.
Leggi
The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials
Kang A, Smyth B, Neuen BL, et al.
Diabetes Obes Metab. 2023;25(8):2151-2162.
Leggi